0 CHECKOUT

Microneedle Drug Delivery Systems to 2020

  • ID: 3501253
  • December 2015
  • Region: Global
  • Greystone Associates
1 of 3

Microneedle technology is attaining commercial viability at a time when drug developers are faced with new challenges as they assess ways to administer new classes of compounds with significant therapeutic potential. The widespread availability of rapid throughput screening is accelerating the discovery of new drugs, a significant number of which are large-molecule therapeutic compounds that cannot tolerate passage through the digestive system, requiring pharmaceutical companies to forego oral formulations and select alternate routes of administration. Microneedle technology has the potential address the growing trend toward self-administration by allowing the precise placement of therapeutic agents at prescribed locations below the skin. To succeed, developers must refine the techniques for large-scale manufacturing and advance the design integration of microneedles into commercially viable drug delivery systems.

What Your Will Learn

- What approved drug products are currently supplied in microneedle devices and systems, what are the device specifics, and who markets them?
- Who are the branded microneedle drug delivery device and system suppliers, their manufacturing READ MORE >

Note: Product cover images may vary from those shown
2 of 3

1. Executive Summary

2. Microneedle Design & Technology
- Microneedle Product Categories
- Solid Microneedles
- Hollow Microneedles
- Coated Microneedles
- Dissolving Microneedles
- Syringe-mounted Microneedles
- Microneedle Arrays & Array Geometries
- Microneedle Manufacturing
- Material Selection Issues
- Fabrication Techniques
- Emerging Fabrication Methods

3. Microneedle Drug Delivery – Market Factors
- Drug Delivery & Self-Administration
- Unmet Needs
- Chronic Conditions & Dosing Frequency
- Patient Safety and Compliance
- Market Drivers
- Shifting Patient Demographics
- Vaccine Dose Sparing
- Managed Care Initiatives
- Government Technology Transfer Programs

4. Microneedle Drug Delivery Assessments
- Branded Platforms
- DebioJect
- Libertas
- MicroCor
- Micronjet
- Soluvia
- MTS
- Branded Devices
- Memspatch
- Micro-Patch
- Combination Products
- Insulin
- V-GO
- PTH
- McirCor PTH
- ZP-PTH
- Abaloparatide-SC
- Development-stage Devices
- Micro-Trans
- Nanopatch
- PKA SoftTouch

5. Near-Terms Markets - Sector Assessments and Forecasts
- Genetic/DNA/Nucleotide Therapeutics
- Insulin
- Metabolic Conditions
- Neurology
- Osteoporosis
- Vaccines

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Pall Corporation
  • Ferring Pharmaceuticals B.V.
  • Medtronic, Inc.
  • SkyePharma AG
  • Heron Therapeutics, Inc.
  • NIPRO Medical Corporation